welcome labcorp earn conference call operator instruction would like turn call cook investor relation please begin cook vice president investor relation thank operator good morning welcome labcorp third quarter conference call detail today press release replay conference call available telephone internet today chairman chief executive officer executive vice president chief financial officer morning investor relation section website labcorp post press release investor relation presentation additional information business operation include reconciliation financial measure financial measure discuss today call additionally make forward look statement forward look statement include limit statement respect estimate guidance relate assumption project impact various factor company business operate financial result cash flow financial condition include pandemic general economic market condition response pandemic future business strategy expect save synergy opportunity future growth forward look statement base upon current expectation subject change base upon various factor many beyond control could affect financial result factor forth detail recent annual report form subsequent quarterly report form company file obligation provide update forward look statement even expectation change turn call chairman president chief executive good morning everyone thank join today labcorp continue leverage innovation science technology accelerate strategy work improve health improve life around world serve trust source health information help customer advance healthcare guide medical decision time remain focus help world pandemic third quarter deliver strong result revenue total billion adjust reach free cash flow million result strong performance improve outlook raise full year guidance revenue adjust free cash flow cover detail minute base business diagnostics drug development perform growth respectively consistent recovery across business diagnostics experience broad geographic recovery base business across test portfolio esoteric routine test demonstrate solid year year growth quarter trail month book bill drug development remain strong drug development continue recover nearly site open business also trial increase versus prior year like turn ongoing role pandemic response labcorp continue support fight pandemic every possible diagnostic drug development capability experience greater anticipate test volume quarter although level period last year time result test remain average result typically available within test volume average quarter second quarter average test volume decline week week since time continue break test base business revenue volume remain difficult forecast also continue maintain high capacity level prepare potential future scenario also another successful quarter bring innovation market notably recently receive emergency authorization combine home collection season upon offer convenient test virus offer available adult child upfront meet clinical guideline addition collaborate prevention treatment trial long antibody combination trial investigational antibody combination demonstrate statistically significant benefit prevent symptomatic reduce severe death outpatient mild moderate promise milestone development treatment also earlier month merck file emergency authorization investigational oral antiviral medicine treatment mild moderate risk adult treatment support phase phase phase clinical trial progress strategy start oncology integration plan lead cancer diagnostic capability extend portfolio solution area additionally launch first clear test monitor residual blood cancer part effort address healthy equity health equity issue recently partner community clinical oncology research network social economic impact cancer care disparity also recently begin work pillar bioscience enhance next generation sequence plan offer specialty oncology assay quarter advance commitment intensify customer focus embed technology data throughout business acquire health lead digital platform trust million woman family plan pregnancy parent support health extend position source woman health insight deep expertise diagnostic genetic specialty test additionally work several organization begin deploy labcorp diagnostic assistant deliver comprehensive result clinical insight directly point care also technology improve health income individual family partner medical home network incorporate test result record safety patient lastly collaboration utilize digital biomarkers drug vaccine device trial enhance clinical trialing offer pursue opportunity long term high growth potential remain focus recent acquisition include myriad test rheumatoid arthritis health advance position growth market make progress integration welcome member join labcorp pipeline remain robust expect continue activity front balance fourth quarter first quarter importantly labcorp continue recognize significant work month name world best employer addition pharma intelligence select labcorp finalist best contract research organization year recognition possible thank diverse talented workforce core ability innovate lastly like provide brief update board management ongoing assessment company structure capital allocation strategy remain commit ensure labcorp best position unlock shareholder value offer patient customer support come expect work closely advisor make significant progress assess capital allocation structure previously share expect update conclusion quarter summarize base business diagnostics drug development strong third quarter position continue success remain dedicate fight deliver strategy carry mission excite progress make ahead take detail third quarter result executive vice president chief financial start comment review third quarter result follow discussion performance segment conclude update full year guidance revenue quarter billion increase last year organic growth acquisition favorable foreign currency translation basis point increase organic revenue drive increase company organic base business partially offset decrease test operate income quarter million revenue quarter million amortization million restructure charge special item exclude item adjust operate income quarter million revenue compare billion last year decrease adjust operate income margin reduction test higher personnel result increase base business demand tight labor market company continue invest workforce partially offset headwind benefit organic base business growth save rate quarter adjust rate exclude restructure charge special item amortization compare last year lower adjust rate primarily geographic earn continue expect full year adjust rate approximately earn quarter million dilute share adjust exclude amortization restructure charge special item quarter last year operate cash flow million quarter compare million year decrease operate cash flow lower cash earn partially offset favorable work capital capital expenditure total million revenue compare million revenue last year result free cash flow million quarter compare million last year quarter million cash flow share repurchase program invest million acquisition review segment performance begin diagnostics revenue quarter billion decrease compare last year organic revenue partially offset acquisition favorable foreign currency translation basis point decrease organic revenue reduction test partially offset increase base business relative third quarter compound annual growth rate base business revenue primarily organic growth total volume increase last year acquisition volume contribute organic volume decrease decrease organic volume decrease test partially offset increase base business reminder include hospital management agreement volume would approximately organic base business volume growth price decrease versus last year lower test partially offset currency acquisition diagnostics organic base business revenue growth compare base business last year come volume come price primarily increase test session diagnostics adjust operate income quarter million revenue compare billion last year decrease adjust operate income margin primarily reduction test higher personnel partially offset organic base business growth save relative third quarter base business margin slightly negative impact diagnostics three year initiative remain track deliver approximately million save year review performance drug development revenue quarter billion increase compare last year organic base business growth acquisition favorable foreign currency translation basis point partially offset lower test perform central business divestiture drug development base business benefit broad base growth across business include vaccine therapeutic work relative third quarter compound annual growth rate base business revenue primarily drive organic growth adjust operate income segment million revenue compare million last year increase adjust operate income primarily organic base business growth save partially offset lower test higher personnel decline adjust operate margin lower test exclude impact test operate margin would compare last year comparability peer drug development earn exclude million expense relate enterprise component bonus include unallocated corporate expense expect full year margin trail month order book bill remain strong billion respectively quarter order negatively impact approximately million significant scope change decrease book bill backlog quarter billion increase compare last year expect approximately billion backlog convert revenue next month full year guidance assume foreign exchange rate effective remainder year raise full year guidance reflect company strong third quarter performance improve outlook remainder year expect enterprise revenue grow prior guidance include benefit foreign currency translation basis point guidance range also include expectation base business grow test expect raise expectation revenue grow diagnostics prior guidance minus plus guidance range include expectation base business grow test revenue expect also raise growth expectation revenue drug development prior guidance current guidance include benefit foreign currency translation basis point guidance range also include expectation base business grow give improve line growth expectation raise adjust guidance prior guidance free cash flow expect billion billion prior guidance billion billion additional comparison purpose also include supplemental deck investor relation website view third quarter result full year guidance compare result summary company another quarter strong performance remain focus perform critical role response global pandemic also grow base business expect drive continue profitable growth base business test volume expect decline remainder year expect continue free cash flow generation acquisition supplement organic growth also return capital shareholder share repurchase program operator take question